Medical Condition News

RSS

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

29 Oct 2010

Researchers identify novel mechanism in control of cell motility

A team of scientists at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Jean-Fran-ois C-t-, Director of the Cytoskeletal Organization and Cell Migration research unit, identified a novel molecular mechanism in the control of cell motility. Their findings were published online today in Current Biology, a journal from the Cell Press group. This scientific breakthrough could eventually lead to the development of new cancer-treating drugs that could block the spread of tumours (metastasis).

29 Oct 2010

New biobank at Qatar helps research of major diseases

A "biobank" of samples and clinical measurements from tens of thousands of people is to be established in Qatar to help scientists understand the causes of major diseases and develop new treatments, it is announced today.

29 Oct 2010

Number of beta cells remains static after age 30: Research

Beta cells, which make insulin in the human body, do not replicate after the age of 30, indicating that clinicians may be closer to better treating diabetes.

29 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

T.J. Martell Foundation celebrates 35th Annual Awards Gala to raise funds for cancer and AIDS research

The T.J. Martell Foundation for Leukemia, Cancer and AIDS Research celebrated its 35th Annual Awards Gala on Wednesday, October 27th, 2010 at the New York Marriott Marquis and raised a total of $1.45 million.

29 Oct 2010

Access to kidney transplantation increases for elderly patients

Elderly patients with kidney failure get kidney transplants more often than they did a decade ago, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The results suggest that the chances of receiving a kidney transplant are better than ever for an older patient who needs one.

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

China CDC signs collaborative agreement with Hutchinson Cancer Research Center

The Chinese Center for Disease Control and Prevention (China CDC) and Fred Hutchinson Cancer Research Center today formalized an ongoing relationship by signing a collaboration agreement. It marks the first such agreement between the China CDC and a U.S. cancer research center.

29 Oct 2010

International Congress at Spain highlights advances in neuroimmunological disease treatment

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology.

29 Oct 2010

VCU Massey receives grant to expand cancer research community program

Virginia Commonwealth University Massey Cancer Center recently was awarded a two-year, $2.4 million grant from the Virginia Tobacco Indemnification and Community Revitalization Commission (Tobacco Commission) to expand the breadth of the center's community involvement and to grow its state-of-the-art clinical research and cancer specialist delivery system.

29 Oct 2010

Study finds impact of pre-transplant BMI on post liver transplant survival in pediatric population

A new study from the University of Washington reported obese children are at increased mortality risk in later years following primary liver transplantation (LT).

29 Oct 2010

Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patients

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.

29 Oct 2010

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

29 Oct 2010

Low household income associated with chronic migraine

New data presented today at The 2010 European Headache and Migraine Trust International Congress (EHMTIC) shows that persons with chronic migraine (headache on greater than or equal to 15 days per month) are much more likely to have annual household incomes below $30,000 than those with episodic migraine (headache on < 15 days per month).

29 Oct 2010

New approach for early diagnosis of pancreatic cancer

Pancreatic tumors are one of the most lethal cancers, with fewer than five percent of patients surviving five years after diagnosis. But a new study that peers deeply into the genetics of pancreatic cancer presents a bit of good news an opportunity for early diagnosis. In contrast to earlier predictions, many pancreatic tumors are, in fact, slow growing, taking nearly 20 years to become lethal after the first genetic perturbations appear.

29 Oct 2010

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced top-line results from ACCORD COPD II, a 12-week Phase III study comparing the efficacy and safety of inhaled aclidinium bromide, an investigative bronchodilator, to placebo in 544 patients with moderate to severe COPD.

29 Oct 2010

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

ACADIA Pharmaceuticals Inc. today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., pursuant to which ACADIA and BLS have agreed to conclude their previously established collaboration to develop and commercialize pimavanserin in the United States and Canada.

29 Oct 2010

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Douglas C. Wallace, Ph.D., a pioneer and internationally prominent scientist in the field of human mitochondrial genetics, has joined The Children's Hospital of Philadelphia to continue his investigations into the role of mitochondrial energy in health and disease.

29 Oct 2010

Non-invasive stool-based screening test detects 64% of colorectal pre-cancers

Exact Sciences today presented data showing that its non-invasive Cologuard stool-based (sDNA) screening test detected 64 percent of colorectal pre-cancers and 85 percent of cancers. The study was conducted in collaboration with Mayo Clinic and examined more than 1,100 patient samples. Results were presented at the 2010 Special Conference for Colorectal Cancer: Biology to Therapy held by the American Association for Cancer Research in Philadelphia, PA.

29 Oct 2010